The majority of patients were under sufficient heart failure therapy with angiotensin-converting enzyme inhibitors (ACEI) or angiotensin-1 receptor (ARB) inhibitors (88.9%), betablockers (BB) (87.5%), and mineralocorticoid receptor antagonists (68.1%) before initiation of ARNI therapy. The gene discussed is NR3C2; the disease is heart failure.